The developer of a sensor designed to continuously monitor indoor spaces for pathogens that could cause pandemics has been given a €500,000 prize by Germany’s Merck KGaA i
A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t
Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.